ChromaDex's Ryan Dellinger to Speak at 248th American Chemical Society National Meeting
Director of Scientific Affairs will present details of the clinical evaluation of ChromaDex's PURENERGY® caffeine alternative
IRVINE, Calif., Aug. 6, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that Ryan Dellinger, Ph.D., director of scientific affairs at ChromaDex, will speak at the 248th American Chemical Society National Meeting on August 10-14.
Dr. Dellinger, who will present on Tuesday, August 12, 2014, will speak at the Division of Agricultural and Food Chemistry's session on high performance foods and beverages about the clinical evaluation of PURENERGY®, ChromaDex's novel caffeine ingredient.
In May 2014, ChromaDex announced the initiation of the second human clinical trial for PURENERGY®. PURENERGY® is an innovative patented caffeine ingredient that is a cocrystal combination of caffeine and ChromaDex's patented pTeroPure® pterostilbene. The combination forms a unique crystalline structure that has superior benefits as compared to caffeine alone. Recently, caffeinated energy products have come under increased regulatory and political scrutiny because of the possible risks associated with consuming high amounts of caffeine. PURENERGY® offers product formulators a unique solution to reduce total caffeine content while optimizing the consumer experience.
In addition to serving as a novel caffeine alternative, PURENERGY™ has additional health benefits stemming from its cocrystal formulation with ChromaDex's patented pTeroPure® pterostilbene, which has shown great promise for supporting heart health, cognitive function, anti-aging, weight loss and other metabolic functions. The findings from the first clinical trial of the pure pTeroPure® (pterostilbene) compound, which were presented in September 2012 at the American Heart Association's High Blood Pressure Research 2012 Scientific Sessions, showed that pTeroPure® (pterostilbene) significantly reduced blood pressure in adults. pTeroPure® was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan.
About ChromaDex:
ChromaDex is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G®, a natural black rice containing cyanidin-3-glucoside; PURENERGY®, a caffeine-pTeroPure® co-crystal; and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation no-flush B vitamin. To learn more about ChromaDex, visit www.chromadex.com.
Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2013, the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
ChromaDex Media Inquiries:
Beckerman PR
Jerry Schranz
201-465-8020
[email protected]
ChromaDex Company Contact:
Laura Kelly, Executive Assistant
949-419-0288
[email protected]
| Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease. |
SOURCE ChromaDex Corp.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article